• Earlier this week, Johnson & Johnson’s Shockwave Medical unit launched the Shockwave C2 Aero coronary intravascular lithotripsy catheter globally, offering improved deliverability, lesion crossing and repositioning for treating calcified coronary artery disease in the U.S. and Japan, with Europe and Canada to follow.
• This next-generation device broadens Johnson & Johnson’s intravascular lithotripsy portfolio in a complex, high-need area of cardiovascular care, reinforcing the company’s MedTech innovation credentials alongside its pharmaceutical pipeline progress.
• We’ll now examine how the launch of Shockwave C2 Aero may influence Johnson & Johnson’s investment narrative around growth in MedTech.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 15 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Johnson & Johnson Investment Narrative Recap

To own Johnson & Johnson, you need to be comfortable with a diversified healthcare story where Innovative Medicine and MedTech offset patent losses and litigation overhangs. The Shockwave C2 Aero launch adds to the MedTech growth angle but does not materially change the key near term swing factors: how well newer drugs replace STELARA revenue and how contained talc litigation and tariff costs remain.

Among the recent updates, the first human data from the OTTAVA robotic surgical system stands out next to Shockwave C2 Aero. Both speak directly to Johnson & Johnson’s push in higher value MedTech, where success in robotics and advanced cardiovascular devices is an important counterbalance to pricing pressure, biosimilars and any earnings drag from acquisitions.

Yet behind the innovation headlines, investors should still pay close attention to the risk that...

Johnson & Johnson's narrative projects $116.5 billion revenue and $26.9 billion earnings by 2029. This requires 6.5% yearly revenue growth and about a $5.9 billion earnings increase from $21.0 billion today.

Uncover how Johnson & Johnson's forecasts yield a $252.96 fair value, a 10% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were assuming revenue of about US$109.9 billion and earnings of US$21.9 billion by 2029, so if you worry that MedTech projects like Shockwave or OTTAVA might underperform, their more pessimistic view on margins and growth shows how far opinions can differ and why it is worth comparing several scenarios yourself.

Explore 10 other fair value estimates on Johnson & Johnson - why the stock might be worth 13% less than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Johnson & Johnson research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Johnson & Johnson research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Johnson & Johnson's overall financial health at a glance.

Searching For A Fresh Perspective?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Invest in the nuclear renaissance through our list of 87 elite nuclear energy infrastructure plays powering the global AI revolution.
• Find 45 companies with promising cash flow potential yet trading below their fair value.
• We've uncovered the 14 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.